AXL is one of the best-known genes involved in TKI resistance (Zhang et al., 2012) and it was demonstrated to confers intrinsic resistance to Osimertinib, a third-generation EGFR TKI that was approved for the treatment of EGFR-T790M-positive NSCLC (Taniguchi et al., 2019). Here, AXL is linked to non-small cell lung carcinoma.